{"id":4300,"date":"2026-11-12T16:00:00","date_gmt":"2026-11-12T20:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4300"},"modified":"2026-11-14T12:48:17","modified_gmt":"2026-11-14T16:48:17","slug":"china-approves-hengrui-angptl3-antibody-for-hofh","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4300","title":{"rendered":"China Approves Hengrui ANGPTL3 Antibody for HoFH"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Hengrui_Therapeutic_Indications-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4317\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Hengrui_Therapeutic_Indications-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Hengrui_Therapeutic_Indications-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Hengrui_Therapeutic_Indications-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Hengrui_Therapeutic_Indications-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Hengrui_Therapeutic_Indications.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Jiangsu Hengrui<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>NMPA approval (China)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Monoclonal antibody (subcutaneous)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Revocimab (SHR-1918)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>ANGPTL3<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Homozygous familial hypercholesterolemia<\/p>\n<h4>Summary<\/h4>\n<p>China approved Hengrui\u2019s subcutaneous ANGPTL3 antibody revocimab (SHR-1918) for LDL-cholesterol lowering in adults and adolescents aged at least 12 with homozygous familial hypercholesterolemia, in combination with diet and other lipid-lowering therapy. This is a China regulatory action, not a global approval.<\/p>\n<p>Hengrui\u2019s exchange disclosure is dated November 12 and appeared in the filing index that day at 16:00 China local time; its corporate release is dated November 13. The approved 300 mg\/2 mL prefilled autoinjector indication is supported by a randomized, double-blind, placebo-controlled Phase 3 trial in patients aged 12 or older. The company reports a placebo-adjusted LDL-C reduction of 64.2% at week 12 and that 88.9% of treated patients reached at least a 50% baseline reduction by week 24. Full trial tables and long-term outcome data were not available in the checked disclosure.<\/p>\n<h4>Deep Analysis<\/h4>\n<p>ANGPTL3 inhibition lowers atherogenic lipoproteins through pathways partly independent of LDL receptor activity, a mechanistic fit for HoFH. <strong>Interpretation A:<\/strong> a large LDL-C reduction in a controlled rare-disease study supports a new domestic treatment option, especially where access to imported evinacumab is constrained.<\/p>\n<p><strong>Interpretation B:<\/strong> reported surrogate improvement may not map directly to cardiovascular outcomes or real-world uptake; complete safety, adherence, pricing, payer and genotype-stratified data are still needed. The comparator was placebo on background treatment, not evinacumab. Domestic approval and trial results cannot be assumed portable to US or EU regulatory standards without full dossier review.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>HoFH is a severe inherited disorder of LDL clearance that causes extreme LDL-C elevation and premature atherosclerosis. Hengrui\u2019s SHR-1918 antibody neutralizes angiopoietin-like protein 3, a regulator of lipoprotein metabolism, to reduce LDL-C.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Signal: a China-origin rare-disease biologic has crossed the approval threshold.<\/li>\n<li>Missing: full published Phase 3 report, safety by age, long-term LDL-C durability, cardiovascular outcomes and reimbursement.<\/li>\n<li>Upgrade: peer-reviewed full dataset and real-world access with persistent lipid control.<\/li>\n<li>Downgrade or falsify: substantial safety or adherence problems or loss of effect over time.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The approval expands the Chinese HoFH toolkit and creates a direct same-target competitor to evinacumab in that market. Relative clinical superiority is not established.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: positive. Confidence in Facts: high for approval and company-reported trial figures. Confidence in Interpretation: moderate for clinical and market effect.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>China approved Hengrui\u2019s subcutaneous ANGPTL3 antibody revocimab (SHR-1918) for LDL-cholesterol lowering in adults and adolescents aged at least 12 with homozygous familial hypercholesterolemia, in combination with diet and other lipid-lowering therapy. This is a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4317,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1291,1483,1482],"class_list":["post-4300","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-hengrui","tag-homozygous-familial-hypercholesterolemia","tag-revocimab"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4300"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4300\/revisions"}],"predecessor-version":[{"id":4325,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4300\/revisions\/4325"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4317"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}